Stifel Financial Corp Reduces Stock Position in Codexis, Inc. (NASDAQ:CDXS)

Stifel Financial Corp decreased its position in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 75.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,673 shares of the biotechnology company's stock after selling 130,513 shares during the period. Stifel Financial Corp owned about 0.05% of Codexis worth $199,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in Codexis by 7.5% in the fourth quarter. Vanguard Group Inc. now owns 4,463,801 shares of the biotechnology company's stock valued at $21,292,000 after buying an additional 311,082 shares in the last quarter. Telemark Asset Management LLC grew its holdings in Codexis by 11.3% in the fourth quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company's stock worth $14,310,000 after purchasing an additional 303,589 shares during the period. Geode Capital Management LLC grew its holdings in Codexis by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 1,855,514 shares of the biotechnology company's stock worth $8,853,000 after purchasing an additional 211,475 shares during the period. Federated Hermes Inc. grew its holdings in shares of Codexis by 1.7% during the fourth quarter. Federated Hermes Inc. now owns 1,278,126 shares of the biotechnology company's stock valued at $6,097,000 after buying an additional 21,767 shares during the last quarter. Finally, CenterBook Partners LP acquired a new position in shares of Codexis during the fourth quarter valued at about $4,688,000. Institutional investors and hedge funds own 78.54% of the company's stock.

Codexis Stock Performance

CDXS stock traded down $0.04 during mid-day trading on Monday, hitting $2.43. The company had a trading volume of 417,786 shares, compared to its average volume of 661,372. The firm has a market cap of $201.31 million, a PE ratio of -2.79 and a beta of 2.56. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. Codexis, Inc. has a 12 month low of $1.90 and a 12 month high of $6.08. The stock's fifty day moving average price is $2.44 and its two-hundred day moving average price is $3.74.

Codexis (NASDAQ:CDXS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.05). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The business had revenue of $7.54 million during the quarter, compared to the consensus estimate of $10.38 million. On average, analysts forecast that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Codexis to a "sell" rating in a report on Friday.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.